IntroductionNew-onset atrial fibrillation (AF) occurs in 5-23% of patients admitted with an acute ST elevation myocardial infarction (STEMI) [1][2][3][4] and is associated with an impaired long-term cardiovascular outcome, including a 40% increase in mortality [5][6][7]. Therefore, predicting AF in STEMI patients can impact clinical practice by identifying patients at increased risk after STEMI. Several biomarkers have been associated with new-onset AF, [8,9] A recent study showed that incident AF after STEMI can be predicted by N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma level assessment [9]. However, in this study, NT-proBNP was assessed somewhere during the first 72 hours after admission and thus there are no data on the temporal relationship between serial NT-proBNP plasma level assessments and mode of onset AF in STEMI patients. The aim of this study was to investigate if assessment of NT-proBNP plasma levels at 3 distinct timings enhances the risk stratification for the development of AF in STEMI patients treated with primary percutaneous coronary intervention (PPCI).
MethodsOur population consisted of patients with a STEMI, who were admitted for PPCI and included in the Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) II study [10,11] a prospective, multi-center, placebo controlled, randomized, clinical trial. The rationale, design and primary results of On-TIME II have been previously described [11].
AbstractBackground: N-terminal pro-Brain Natriuretic Peptide(NT-proBNP)is associated with atrial fibrillation(AF) in the setting of acute ST-elevation myocardial infarction (STEMI), and the present study was aimed at assessing the temporal association between NT-proBNP and incident AF.